Corcept president Sean Maduck sells $2.86m in stock

On September 1, 2026, Sean Maduck, President of Corcept, sold 25,000 shares of the company's common stock, worth approximately $2.86 million. The sales were conducted under a pre-established 10b5-1 trading plan, adopted by Maduck on December 8, 2025. The stock price during the transactions ranged from $113.36 to $115.82 per share.

Meanwhile, Corcept shares have seen a 224% year-to-date increase, trading at $112.80 with a market capitalization of $12.19 billion. These transactions follow a significant personal acquisition of 25,000 shares by Maduck, made by exercising stock options at $8.27 per share, valued at $206,750. Maduck also acquired 150 shares through a company purchase plan at $113.38 per share, and received 150 shares of unvested restricted stock awards under the same plan.

On September 2, 2026, 117 shares were withheld by Corcept to cover tax obligations. As of September 1, 2026, Maduck directly owns 9,938 shares and indirectly holds shares through various entities including trusts and LLCs. Despite the recent stock sales, Corcept Therapeutics reported impressive second-quarter 2026 earnings, with revenue reaching $256.1 million, a 32% increase from the previous year, surpassing expectations.